Mazor Robotics’ Guidance System Successfully Completes its 10,000th Procedure
April 28 2015 - 7:37AM
Business Wire
- System installed in over 80 hospitals and
medical centers in the US, Asia and Europe -
- More than half of the procedures were
performed in the US -
Mazor Robotics Ltd. (TASE:MZOR; NASDAQ GM: MZOR), a developer of
innovative guidance systems and complementary products, announced
today that the 10,000th spinal surgery in which Mazor Robotics’
guidance system (Renaissance as well as the earlier Spine Assist)
was used has been completed successfully. The Renaissance Guidance
System was launched in mid 2012 and is being used by orthopedic and
neurosurgeons to perform a wide range of spine and brain
surgeries.
“As we approach 50 Renaissance Guidance Systems in the US, our
goal is to accelerate the adoption of the system, to make it the
standard of care for spinal surgeons across the country,” said Ori
Hadomi, CEO of Mazor Robotics. “While we are very proud of the
tools we have built for the surgeons using Renaissance, what is
most rewarding for the team at Mazor is to see the way our system
enables patients to quickly get back on their feet and resume their
daily activities, a reality that many would have thought impossible
only a few years ago.”
Renaissance improves the execution and results in a wide variety
of spine procedures, including minimally-invasive and percutaneous
degenerative repair, vertebrae stabilization and fixation for
complex spinal deformity as well as vertebral augmentation. To
date, Renaissance has been used in over 1,000 complex spinal
deformity correction procedures and thousands of minimally invasive
procedures. Additionally, Renaissance has been used in a variety of
brain operations, including Deep Brain Stimulation procedures.
There is a growing body of clinical data on the Renaissance
Guidance System with over 50 publications in major professional
journals and podium presentations at major international meetings,
demonstrating the superior performance over standard techniques.
Demonstrating the flexibility of the system, the youngest patient
to be operated on using Renaissance was five years old and the
oldest patient was 92 years old.
By affording orthopedic and neurosurgeons the ability to create
a pre-operative blueprint of the ideal surgery for each patient in
a virtual 3D environment as well as providing them with a
sophisticated guidance system, Renaissance gives surgeons the peace
of mind that they can perform simple as well as complex procedures
with predictable results and potentially through a much less
invasive approach.
“I have been incorporating Mazor Robotics technology into my
practice for over five years now,” said pediatric orthopedic
surgeon Dr. Dennis Devito of Children's Orthopedics of Atlanta
(COA), GA. “I find it provides improved patient care through
enhancement of the surgeon’s capabilities. As a surgeon that has
many patients with severe spinal deformity, the Renaissance
Guidance System allows me to visualize and plan my surgery so I can
focus my attention on correcting my patients’ curve.”
Mazor anticipates its Renaissance Guidance System will be used
in over three thousand spine and brain procedures in 2015. As
surgeons and hospital administrators become more broadly aware of
its benefits, the Company expects this to significantly grow over
the coming years as the number of systems and surgeons using
Renaissance increases.
About Mazor
Mazor Robotics (TASE: MZOR; NASDAQGM: MZOR) believes in healing
through innovation by developing and introducing revolutionary
robotic-based technology and products aimed at redefining the gold
standard of quality care. Mazor Robotics Renaissance® Guidance
System enables surgeons to conduct spine and brain procedures in a
more accurate and secure manner. For more information, please visit
www.MazorRobotics.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
and other securities laws. Any statements in this release about
future expectations, plans or prospects for the Company, including
without limitation, statements regarding the acceleration of the
adoption of the Renaissance Guidance System to make it the standard
of care for spinal surgeons across the country, the benefits of the
Renaissance, our expectation that Renaissance will be used in over
three thousand spine and brain procedures in 2015 and that the
number of such procedures will significantly grow over the coming
years, and other statements containing the words “believes,”
“anticipates,” “plans,” “expects,” “will” and similar expressions
are forward-looking statements. These statements are only
predictions based on Mazor's current expectations and projections
about future events. There are important factors that could cause
Mazor's actual results, level of activity, performance or
achievements to differ materially from the results, level of
activity, performance or achievements expressed or implied by the
forward-looking statements. Those factors include, but are not
limited to, the impact of general economic conditions, competitive
products, product demand and market acceptance risks, reliance on
key strategic alliances, fluctuations in operating results, and
other factors indicated in Mazor's filings with the Securities and
Exchange Commission (SEC) including those discussed under the
heading "Risk Factors" in Mazor’s annual report on Form 20-F filed
with the SEC on April 9, 2014 and in subsequent filings with the
SEC. For more details, refer to Mazor's SEC filings. Mazor
undertakes no obligation to update forward-looking statements to
reflect subsequent occurring events or circumstances, or to changes
in our expectations, except as may be required by law.
Stephani Shipman, (407) 591-3461Marketing Communications
ManagerMazor Robotics, Inc.s.shipman@mazorrobotics-us.comorMichael
Polyviou/Robert Jones –
Investorsmpolyviou@evcgroup.com; bjones@evcgroup.com212.850.6020;
646.201.5447
Mazor Robotics (NASDAQ:MZOR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Mazor Robotics (NASDAQ:MZOR)
Historical Stock Chart
From Apr 2023 to Apr 2024